History

  • 2019Spread wings

    03.

    1st in-house training with European distributor, BeDia Genomics France

    NGeneAnalySys updated version released

    02.

    Attending MEDICA 2019 in Dubai, UAE

    Partnerships with Types of Technology Est. in Saudi Arabia, PT. Luhur Wiratama in Indonesia, and Sure Bio Diagnostics & Pharmaceuticals in Pakistan

    01.

    Partnership with BeDia Genomics in France

  • 2018Take off to the world

    12.

    ISO 13485 2016 certificate received

    11.

    HEMEaccuTest™ CE-IVD approved

    Attending MEDICA2018 in Düsseldorf, Germany

    10.

    Partnerships with BioMed Global Singapore and Ozgun Kimya A.S. Turkey

    09.

    ISO 9001 certificate received

    08.

    2nd oversea a demonstration of HEMEaccuTest™ and BRCAaccuTest™ PLUS in Singapore

    ISO 13485 and ISO 9001 inspection

    07.

    Attending FEME 2018 in Florida and AACC 2018 in Chicago, USA

    05.

    1st oversea demonstration of BRCAaccuTest™ PLUS in Italy

    Partnership with AmitisGen Med TECH Group, Iran

    02.

    Attending MEDLAB 2018 in Dubai, UAE

  • 2017Technology commercialization

    07.

    Institutional review board registered for in vitro diagnostic reagent

    06.

    BRCAaccuTest™ & NGeneAnalySys™ CE-IVD approved

    05.

    ISO13485 certificated NGS software

    04.

    Korean Ministry of Food and Drug Safety approved clinical trail for NGS panel

    02.

    GMP certification for NGS software and in vitro diagnosis medical device & quality criterion

    01.

    Released NGeneAnalySys™

  • 2016Commercialization foundation

    12.

    Acquired ISO 9001, 13485 Certification

    11.

    Contracted development and development of chemotherapy drug development project

    10.

    Acquired GMP certification for in vitro diagnostic reagent

    08.

    Selected for Intellectual Property R&D

    07.

    Genetic Testing Agency Approved

    06.

    Launched NGS based breast cancer panel & S/W (illumina MiSeq & MiSeq Dx), Selected as a project to commercialize fetal genetic diseases

    05.

    Selected as an NGS disease analysis platform commercialization project

    03.

    Designated as a venture enterprise

  • 2015Established NGeneBio

    12.

    Built NGS Molecular Laboratory

    11.

    Selected NGS based chemotherapy diagnosis project, the establishment of a company-affiliated research institute

    10.

    Established NGeneBio Co., Ltd.

    Established NGeneBio and Spin off

  • 2014

    12.

    Launched cloud-based genome service, established Korea Telecom company No. 1